Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Obtaining accurate drug response data in large cohorts of cancer patients is very challenging; thus, most cancer pharmacogenomics discovery is conducted in preclinical studies, typically using cell lines and mouse models. However, these platforms suffer from serious limitations, including small sample sizes. Here, we have developed a novel computational method that allows us to impute drug response in very large clinical cancer genomics data sets, such as The Cancer Genome Atlas (TCGA). The approach works by creating statistical models relating gene expression to drug response in large panels of cancer cell lines and applying these models to tumor gene expression data in the clinical data sets (e.g., TCGA). This yields an imputed drug response for every drug in each patient. These imputed drug response data are then associated with somatic genetic variants measured in the clinical cohort, such as copy number changes or mutations in protein coding genes. These analyses recapitulated drug associations for known clinically actionable somatic genetic alterations and identified new predictive biomarkers for existing drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 4×
“One final consequence of our work is that TCGA can now be used to study mechanisms of drug response, similar to drug screening data sets such as GDSC and CCLE.”
InfluentialSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 15×
“Indeed, following the example of studies like TCGA and GDSC, we have made all analyses, code, and results publicly accessible (see Software Availability).”
InfluentialAsangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882 · cited 1×
“Nutlin-3a targets TP53 , and there are multiple studies showing that mir-21 , which is a known oncogene (Asangani et al. 2008), also targets TP53 (Ma et al. 2013), thus giving a clear mechanism for this observed association.”
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
The Extent and Consequences of P-Hacking in Science
Head, M. L., Holman, L., Lanfear, R., Kahn, A. T., & Jennions, M. D. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002106 · Cited by 1,388 · cited 2×
“Here, we have explicitly avoided fitting multiple models to the data and selecting that which performed best, a practice that leads to irrepro-ducible results (Head et al. 2015).”
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813 · cited 2×
“However, there are other cell line data sets (e.g., CCLE, CTRP) that contain additional drugs, which could be interro-gated using this methodology.”
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555 · cited 2×
“curs because of copy number amplification (CNA) of a large region of Chromosome 17 known as the ERBB2 amplicon (Kallioniemi et al. 1992).”
Inconsistency in large pharmacogenomic studies
Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013) · Nature · doi:10.1038/nature12831 · Cited by 499 · cited 2×
“2007) and ongoing debates surrounding the reliability of drug screens in cell lines (Haibe-Kains et al. 2013; Stransky et al. 2015;Geeleher et al. 2016b).”
Cited by
Maeser, D., Gruener, R. F., & Huang, R. S. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab260 · Cited by 1,791
Self-citationMOLI: multi-omics late integration with deep neural networks for drug response prediction
Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C., & Ester, M. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz318 · Cited by 421
Koromina, M., Pandi, M.-T., & Patrinos, G. P. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0151 · Cited by 140
“Geeleher et al. (2017) proposed a methodology that allowed the use of clinical cancer sequencing datasets, such as the TCGA data, for the identification of pharmacogenomics biomarkers without requiring the collection of drug responses from the patients (Geeleher et al., 2017).”
Goel, I., Bhaskar, Y., Kumar, N., Singh, S., Amanullah, M., Dhar, R., & Karmakar, S. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1550407 · Cited by 31
Metadata
- Authors
- Geeleher, P., Zhang, Z., Wang, F., Gruener, R. F., Nath, A., Morrison, G., Bhutra, S., Grossman, R. L., & Huang, R. S.
- Venue
- Genome Research
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-08-28
- Volume
- 27
- Issue
- 10
- Pages
- 1743-1751
- ISSN
- 1088-9051 (ISSN-L)
- 1549-5469
- OpenAlex
- W2747036018
- Cited by
- 138
- References
- 12
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. https://app.cochat.ai/papers/10.1101/gr.221077.117
- The paper
- Geeleher, P., Zhang, Z., Wang, F., Gruener, R. F., Nath, A., Morrison, G., Bhutra, S., Grossman, R. L., & Huang, R. S. (2017). Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Research. https://doi.org/10.1101/gr.221077.117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.